Table 1 Characteristics of study population
Characteristics | Number | Percent (%) |
|---|---|---|
Total participants | 2938 | 100.0 |
Sex | ||
Male | 1557 | 53.0 |
Female | 1381 | 47.0 |
Primary diagnosis | ||
Leukemia | 1000 | 34.0 |
Lymphoma | 547 | 18.6 |
Embryonal tumorsa | 393 | 13.4 |
CNS tumors | 373 | 12.7 |
Bone & soft tissue sarcoma | 361 | 12.3 |
Other diagnoses | 264 | 9.0 |
Chemotherapy exposures | ||
Vinca alkaloids | 2099 | 71.4 |
Anthracyclines | 1676 | 57.0 |
Alkylating agents, classic | 1665 | 56.7 |
Antimetabolites | 1418 | 48.3 |
Corticosteroids | 1336 | 45.5 |
Epipodophyllotoxins | 1034 | 35.2 |
Asparaginase enzymes | 924 | 31.4 |
Radiation therapy (RT) | ||
Brain-RT | 779 | 26.5 |
Body-trunk-RTb | 783 | 26.7 |
Chest-RT | 608 | 20.7 |
Abdominal-RT | 536 | 18.2 |
Pelvic-RT | 461 | 15.7 |
Cardiometabolic Risk Factors (prevalentc) | N/N at Risk | Percent (95% CI) |
Obesity | 1201/2929 | 41.0 (39.2–42.8) |
Hypertension | 842/2882 | 29.2 (37.6–30.9) |
Hypertriglyceridemia | 595/2914 | 20.4 (19.0–21.9) |
Hypercholesterolemia | 477/2914 | 16.4 (15.0–17.8) |
Abnormal glucose | 304/2936 | 10.4 (9.3–11.5) |
Cardiometabolic risk factors (incidentd) | N/N at Risk | Percent (95% CI) |
Obesity | 255/2929 | 8.7 (7.7–9.8) |
Hypertension | 201/2882 | 7 (6.1–8) |
Hypertriglyceridemia | 80/2914 | 2.7 (2.2–3.4) |
Hypercholesterolemia | 50/2914 | 1.7 (1.3–2.3) |
Abnormal glucose | 74/2936 | 2.5 (2–3.2) |
Age, years | Median | (IQR) |
Age at diagnosis | 6.1 | (2.8–12.6) |
Age at DNA sampling | 30.1 | (21.6–38) |
Age at clinical follow-up | 33.4 | (25.4–41.8) |
